Inovio Pharmaceuticals, Inc. (INO) Stock Analysis & Investment Frameworks
Inovio Pharmaceuticals, Inc. (INO) stock analysis on Invetso. Review Inovio Pharmaceuticals, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Inovio Pharmaceuticals, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Inovio Pharmaceuticals, Inc. Key Financial Metrics
- Market Cap: $80.34M
- Revenue: $65343.00
- ROE: -1005.80%
- ROIC: -640.60%
- Dividend Yield: N/A
About Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.
Inovio Pharmaceuticals, Inc. Investment Frameworks
Invetso analyzes Inovio Pharmaceuticals, Inc. (INO) across the following frameworks:
- Inovio Pharmaceuticals, Inc. 10Y Growth Potential
- Inovio Pharmaceuticals, Inc. Scenario Analysis
- Inovio Pharmaceuticals, Inc. Risks & Opportunities
- Inovio Pharmaceuticals, Inc. Economic Moat
- Inovio Pharmaceuticals, Inc. Business Model
- Inovio Pharmaceuticals, Inc. Management
- Inovio Pharmaceuticals, Inc. SWOT Analysis
- Inovio Pharmaceuticals, Inc. Porter's 5 Forces
- Inovio Pharmaceuticals, Inc. PESTLE Analysis
- Inovio Pharmaceuticals, Inc. ESG Analysis